midodrine has been researched along with Neurally Mediated Faint in 45 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All studies were conducted in clinical syncope populations and compared the benefit of midodrine vs." | 9.22 | Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis. ( Lei, LY; Raj, SR; Sheldon, RS, 2022) |
| " All studies were conducted in clinical syncope populations and compared the benefit of midodrine vs." | 5.22 | Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis. ( Lei, LY; Raj, SR; Sheldon, RS, 2022) |
| " After one week the dosage will be up-titrated to midodrine 30 mg/day and fludrocortisone 0." | 3.01 | Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial. ( Akbarzadeh, MA; Alaeddini, F; Aminorroaya, A; Apakuppakul, S; Ariannejad, H; Bozorgi, A; Emkanjoo, Z; Jalali, A; Joharimoghadam, A; Kiarsi, M; Mohammadi, R; Mohsenizade, A; Mollazadeh, R; Ngarmukos, T; Oraii, A; Oraii, S; Rahimi, B; Sadeghian, S; Shahabi, J; Tajdini, M; Tavolinejad, H, 2021) |
| "Recurrent vasovagal syncope is common, responds poorly to treatment, and causes physical trauma and poor quality of life." | 3.01 | Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial. ( Ayala-Paredes, F; Faris, P; Guzman, J; Krahn, AD; Kus, T; Marquez, M; Maxey, C; Morillo, CA; Raj, SR; Ritchie, D; Safdar, S; Sheldon, R; Tang, A, 2021) |
| "Midodrine is a pro-drug whose primary metabolite is an alpha-1 adrenoreceptor agonist." | 2.77 | Rationale for the prevention of syncope trial IV: assessment of midodrine. ( Faris, PD; McRae, M; Raj, SR; Sheldon, RS, 2012) |
| "Initial treatment of vasovagal syncope (VVS) consists of advising adequate fluid and salt intake, regular exercise, and physical counterpressure manoeuvres." | 2.76 | Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). ( Go-Schön, IK; Reitsma, JB; Romme, JJ; van Dijk, N; Wieling, W, 2011) |
| "Midodrine is an alpha-agonist prodrug of desglymidodrine (DGM) that has been reported to be of clinical benefit in patients with neurocardiogenic syncope." | 2.73 | Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study. ( Champlain, Jd; Lamarre-Cliche, M; Larochelle, P; Souich, Pd, 2008) |
| "Treatment with atenolol, midodrine and their combination prevented VVS in 89% patients." | 2.72 | [Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes]. ( Al'bitskaia, KV; Golitsyn, SP; Kheĭmets, GI; Kuchinskaia, EA; Pevzner, AV; Rogoza, AN; Vershuta, EV, 2006) |
| "Midodrine was given at a starting dose of 5 mg three times a day and increased up to a dose of 15 mg three times a day when required." | 2.70 | Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. ( Akhtar, M; Bash, D; Beheiry, S; Jaeger, F; Leonelli, FM; Natale, A; Pavia, S; Perez-Lugones, A; Saliba, W; Schweikert, R; Shewchik, J; Sra, J; Tchou, PJ; Tomassoni, GF, 2001) |
| "Therapy of vasovagal syncope is still a subject of debate." | 2.69 | Midodrine hydrochloride in the treatment of vasovagal syncope. ( Mitro, P; Rybár, AR; Trejbal, D, 1999) |
| "Syncope is a common symptom and accounts for approximately 1% of all emergency visits." | 2.46 | Evaluation and management of syncope. ( Borggrefe, M; Schimpf, R; Veltmann, C; Wolpert, C, 2010) |
| "Vasovagal syncope is a common disorder of autonomic cardiovascular regulation." | 2.40 | Pharmacologic approaches to therapy for vasovagal syncope. ( Calkins, H, 1999) |
| "In the OI spectrum, postural tachycardia syndrome (POTS) accounted for 826 cases (39." | 1.72 | [A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children]. ( Chen, YH; Cui, YX; DU, JB; Jin, HF; Liao, Y; Liu, P; Liu, XQ; Qi, JG; Sun, CF; Sun, Y; Wang, YL; Xu, WR; Yan, H; Zhang, CY; Zhang, QY, 2022) |
| "Vasovagal syncope is the most common cause of syncope in childhood and its treatment is not at a satisfactory level yet." | 1.62 | Midodrine treatment in children with recurrent vasovagal syncope. ( Atik, F; Bagrul, D; Ece, I; Kavurt, AV; Yılmaz, A, 2021) |
| "Pirmenol treatment was not associated with syncope during ordinary HUT, but nausea, sweating, and syncope occurred during HUT with provocative administration of isosorbide dinitrate." | 1.32 | A patient responding to combined therapy with pirmenol and midodrine for refractory neurally mediated syncope complicated by prostatic hypertrophy. ( Emi, S; Ishimoto, T; Kageyama, N; Mizuguchi, Y; Nagase, N; Oishi, Y; Oki, T, 2004) |
| "Midodrine was initially administered orally at a dose of 2." | 1.30 | Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. ( Akhtar, M; Biehl, M; Blanck, Z; Deshpande, S; Dhala, A; Jazayeri, MR; Maglio, C; Sra, J, 1997) |
| "Pharmacological therapy of neurocardiogenic syncope is often limited by the relatively low response rate to such treatment." | 1.30 | Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers. ( Credner, S; Hohnloser, SH; Klingenheben, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (15.56) | 18.2507 |
| 2000's | 18 (40.00) | 29.6817 |
| 2010's | 8 (17.78) | 24.3611 |
| 2020's | 12 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Thorens, A | 1 |
| Lei, LY | 1 |
| Raj, SR | 3 |
| Sheldon, RS | 4 |
| Shaughnessy, AF | 1 |
| Gerber, C | 1 |
| Hatoum, T | 1 |
| Raj, S | 1 |
| Cui, YX | 1 |
| DU, JB | 1 |
| Zhang, QY | 1 |
| Liao, Y | 2 |
| Liu, P | 1 |
| Wang, YL | 1 |
| Qi, JG | 1 |
| Yan, H | 1 |
| Xu, WR | 1 |
| Liu, XQ | 1 |
| Sun, Y | 1 |
| Sun, CF | 1 |
| Zhang, CY | 1 |
| Chen, YH | 1 |
| Jin, HF | 1 |
| Behnoush, AH | 2 |
| Yazdani, K | 2 |
| Khalaji, A | 2 |
| Tavolinejad, H | 3 |
| Aminorroaya, A | 3 |
| Jalali, A | 3 |
| Tajdini, M | 3 |
| Cannom, DS | 1 |
| Bagrul, D | 1 |
| Ece, I | 1 |
| Yılmaz, A | 1 |
| Atik, F | 1 |
| Kavurt, AV | 1 |
| Sadeghian, S | 1 |
| Alaeddini, F | 1 |
| Emkanjoo, Z | 1 |
| Mollazadeh, R | 1 |
| Bozorgi, A | 1 |
| Oraii, S | 1 |
| Kiarsi, M | 1 |
| Shahabi, J | 1 |
| Akbarzadeh, MA | 1 |
| Rahimi, B | 1 |
| Joharimoghadam, A | 1 |
| Mohsenizade, A | 1 |
| Mohammadi, R | 1 |
| Oraii, A | 1 |
| Ariannejad, H | 1 |
| Apakuppakul, S | 1 |
| Ngarmukos, T | 1 |
| Brignole, M | 1 |
| Sheldon, R | 1 |
| Faris, P | 1 |
| Tang, A | 1 |
| Ayala-Paredes, F | 1 |
| Guzman, J | 1 |
| Marquez, M | 1 |
| Morillo, CA | 1 |
| Krahn, AD | 1 |
| Kus, T | 1 |
| Ritchie, D | 1 |
| Safdar, S | 1 |
| Maxey, C | 1 |
| Hutt Centeno, E | 1 |
| Mayuga, KA | 1 |
| Li, Y | 1 |
| Li, H | 1 |
| Li, X | 3 |
| Jin, H | 1 |
| Lamarre-Cliche, M | 1 |
| Souich, Pd | 1 |
| Champlain, Jd | 1 |
| Larochelle, P | 1 |
| Kuriachan, V | 1 |
| Platonov, M | 1 |
| Zhang, Y | 1 |
| Chen, S | 1 |
| Tang, C | 1 |
| Du, J | 1 |
| Liu, XY | 1 |
| Wang, C | 1 |
| Wu, LJ | 1 |
| Hu, CY | 1 |
| Lin, P | 1 |
| Li, MX | 1 |
| Cui, XL | 1 |
| Xie, ZW | 1 |
| Paling, D | 1 |
| Vilches-Moraga, A | 1 |
| Akram, Q | 1 |
| Atkinson, O | 1 |
| Staniland, JR | 1 |
| Paredes-Galán, E | 1 |
| Veltmann, C | 1 |
| Borggrefe, M | 1 |
| Wolpert, C | 1 |
| Schimpf, R | 1 |
| Romme, JJ | 1 |
| van Dijk, N | 1 |
| Go-Schön, IK | 1 |
| Reitsma, JB | 1 |
| Wieling, W | 1 |
| Oz, F | 1 |
| Cizgici, Y | 1 |
| Bilge, AK | 1 |
| Faris, PD | 1 |
| McRae, M | 1 |
| Kaufmann, H | 1 |
| Saadia, D | 1 |
| Voustianiouk, A | 1 |
| Kuchinskaia, EA | 3 |
| Pevzner, AV | 3 |
| Vershuta, EV | 3 |
| Al'bitskaia, KV | 3 |
| Kheĭmets, GI | 2 |
| Rogoza, AN | 3 |
| Golitsyn, SP | 3 |
| Kheĭmetz, GI | 1 |
| Tripoten', MI | 1 |
| Mizuguchi, Y | 1 |
| Ishimoto, T | 1 |
| Kageyama, N | 1 |
| Oishi, Y | 1 |
| Emi, S | 1 |
| Nagase, N | 1 |
| Oki, T | 1 |
| Chen, LY | 1 |
| Shen, WK | 1 |
| Gracie, J | 1 |
| Newton, JL | 1 |
| Norton, M | 1 |
| Baker, C | 1 |
| Freeston, M | 1 |
| Stewart, JM | 1 |
| Qingyou, Z | 1 |
| Junbao, D | 1 |
| Chaoshu, T | 1 |
| Amaki, M | 1 |
| Kamide, K | 1 |
| Takiuchi, S | 1 |
| Niizuma, S | 1 |
| Horio, T | 1 |
| Kawano, Y | 1 |
| Sra, J | 2 |
| Maglio, C | 1 |
| Biehl, M | 1 |
| Dhala, A | 1 |
| Blanck, Z | 1 |
| Deshpande, S | 1 |
| Jazayeri, MR | 1 |
| Akhtar, M | 2 |
| Ward, CR | 1 |
| Gray, JC | 1 |
| Gilroy, JJ | 1 |
| Kenny, RA | 1 |
| Klingenheben, T | 1 |
| Credner, S | 1 |
| Hohnloser, SH | 1 |
| Dubin, AM | 1 |
| Van Hare, GF | 1 |
| Calkins, H | 1 |
| Mitro, P | 1 |
| Trejbal, D | 1 |
| Rybár, AR | 1 |
| Samniah, N | 2 |
| Iskos, D | 2 |
| Sakaguchi, S | 2 |
| Lurie, KG | 2 |
| Benditt, DG | 2 |
| Perez-Lugones, A | 1 |
| Schweikert, R | 1 |
| Pavia, S | 1 |
| Jaeger, F | 1 |
| Tomassoni, GF | 1 |
| Saliba, W | 1 |
| Leonelli, FM | 1 |
| Bash, D | 1 |
| Beheiry, S | 1 |
| Shewchik, J | 1 |
| Tchou, PJ | 1 |
| Natale, A | 1 |
| Low, PA | 1 |
| Wiley, TM | 1 |
| Luu, VD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Compression Stockings for Treating Vasovagal Syncope (COMFORTS II) Trial; a Double Blind, Multi-center Randomized Controlled Trial[NCT05086679] | 268 participants (Anticipated) | Interventional | 2022-03-14 | Recruiting | |||
| Comparison of Outcomes With Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS Trial)[NCT04595942] | Phase 3 | 1,375 participants (Anticipated) | Interventional | 2020-11-19 | Recruiting | ||
| Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4)[NCT01456481] | Phase 4 | 134 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| Effect of Cardioneuroablation vs Midodrine on Syncope Recurrence Among Patients With Vasovagal Syncope: The CAMPAIGN Randomized Clinical Trial[NCT05803148] | 184 participants (Anticipated) | Interventional | 2023-04-05 | Recruiting | |||
| CardioneuROablation for Reflex Syncope: Effects on autonoMic cArdiac Regulation and Efficacy Assessment - the Roman Syncope Study.[NCT03903744] | 48 participants (Actual) | Interventional | 2018-11-01 | Completed | |||
| A Pilot Study to Assess Sinusoidal Galvanic Vestibular Stimulation in Neurogenic Orthostatic Hypotension[NCT04976101] | 0 participants (Actual) | Interventional | 2023-01-01 | Withdrawn (stopped due to It never enrolled any patients) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for midodrine and Neurally Mediated Faint
| Article | Year |
|---|---|
Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis.
Topics: Double-Blind Method; Female; Humans; Male; Midodrine; Randomized Controlled Trials as Topic; Syncope | 2022 |
Current approach to the treatment of vasovagal syncope in adults.
Topics: Adult; Aged; Humans; Midodrine; Quality of Life; Randomized Controlled Trials as Topic; Syncope, Vas | 2023 |
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Evidence-based treatment for vasovagal syncope.
Topics: Evidence-Based Medicine; Fludrocortisone; Humans; Midodrine; Pacemaker, Artificial; Selective Seroto | 2008 |
alpha-Adrenoceptor agonists for the treatment of vasovagal syncope: a meta-analysis of worldwide published data.
Topics: Adrenergic alpha-Agonists; Etilefrine; Humans; Midodrine; Outcome Assessment, Health Care; Randomize | 2009 |
Evaluation and management of syncope.
Topics: Diagnosis, Differential; Electrocardiography; Humans; Hypotension, Orthostatic; Midodrine; Practice | 2010 |
Neurocardiogenic syncope: latest pharmacological therapies.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Fluoxetine; Heart | 2006 |
Advances in the treatment of cardiac rhythm disturbances.
Topics: Adrenergic alpha-Agonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Electrophysiolog | 1999 |
Pharmacologic approaches to therapy for vasovagal syncope.
Topics: Atenolol; Fludrocortisone; Humans; Midodrine; Paroxetine; Randomized Controlled Trials as Topic; Syn | 1999 |
14 trials available for midodrine and Neurally Mediated Faint
| Article | Year |
|---|---|
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age | 2021 |
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age | 2021 |
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age | 2021 |
Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Midodrine; Syncope, Vasovagal; Vasoconstrictor Age | 2021 |
Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study.
Topics: Adult; Autonomic Nervous System; Blood Pressure; Chromatography, High Pressure Liquid; Cross-Over St | 2008 |
[Efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope].
Topics: Adolescent; Child; Female; Follow-Up Studies; Humans; Male; Midodrine; Syncope, Vasovagal; Tilt-Tabl | 2009 |
Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial).
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Cross-Over Studies; Double-Blind Method; Exercise; Fema | 2011 |
Rationale for the prevention of syncope trial IV: assessment of midodrine.
Topics: Adrenergic alpha-1 Receptor Agonists; Humans; Intention to Treat Analysis; Midodrine; Multicenter St | 2012 |
Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study.
Topics: Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Hypotens | 2002 |
[Results of midodrin treatment of vasovagal syncope].
Topics: Adolescent; Adult; Aged; Drug Tolerance; Female; Humans; Male; Middle Aged; Midodrine; Syncope, Vaso | 2004 |
[Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes].
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Drug Ther | 2006 |
The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope.
Topics: Adolescent; Adrenergic alpha-Agonists; Child; Female; Humans; Male; Midodrine; Syncope, Vasovagal | 2006 |
Midodrine: a role in the management of neurocardiogenic syncope.
Topics: Adrenergic alpha-Agonists; Blood Pressure; Cardiography, Impedance; Cross-Over Studies; Double-Blind | 1998 |
Midodrine hydrochloride in the treatment of vasovagal syncope.
Topics: Adrenergic alpha-Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; F | 1999 |
Efficacy and safety of midodrine hydrochloride in patients with refractory vasovagal syncope.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Age | 2001 |
Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study.
Topics: Adrenergic alpha-Agonists; Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Human | 2001 |
22 other studies available for midodrine and Neurally Mediated Faint
| Article | Year |
|---|---|
Topics: Humans; Midodrine; Syncope, Vasovagal; Treatment Outcome | 2021 |
Midodrine Is Worth a Trial in People With Frequent Episodes of Vasovagal Syncope.
Topics: Humans; Midodrine; Recurrence; Syncope, Vasovagal | 2022 |
Topics: Health Status; Humans; Midodrine; Quality of Life; Syncope, Vasovagal; Treatment Outcome | 2022 |
[A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children].
Topics: Child; Electrolytes; Female; Humans; Male; Metoprolol; Midodrine; Orthostatic Intolerance; Postural | 2022 |
Management of coexistent neurogenic orthostatic hypotension and supine hypertension.
Topics: Accidental Falls; Central Nervous System Agents; Droxidopa; Drug Substitution; Female; Humans; Hyper | 2019 |
Midodrine treatment in children with recurrent vasovagal syncope.
Topics: Adolescent; Child; Humans; Midodrine; Recurrence; Retrospective Studies; Syncope, Vasovagal | 2021 |
Establishing the Efficacy of Midodrine to Prevent Vasovagal Syncope.
Topics: Humans; Midodrine; Syncope, Vasovagal | 2021 |
Summary for Patients: Midodrine to Prevent Fainting.
Topics: Adult; Humans; Midodrine; Syncope, Vasovagal; Vasoconstrictor Agents | 2021 |
What can I do when first-line measures are not enough for vasovagal syncope?
Topics: Adrenergic beta-Antagonists; Adult; Combined Modality Therapy; Female; Fludrocortisone; Head-Down Ti | 2018 |
Prognostic analysis of orthostatic intolerance using survival model in children.
Topics: Adolescent; Child; Female; Humans; Male; Metoprolol; Midodrine; Orthostatic Intolerance; Prognosis; | 2014 |
Midodrine hydrochloride is safe and effective in older people with neurocardiogenic syncope.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Follow | 2010 |
A patient treated with tilt training and midodrine after 68 seconds asystole during head-up tilt table testing.
Topics: Combined Modality Therapy; Electrocardiography; Heart Arrest; Humans; Male; Midodrine; Physical Ther | 2011 |
[Successful midodrin treatment for vasovagal syncopes accompanied by asystole].
Topics: Adrenergic alpha-Agonists; Adult; Atropine; Electrocardiography; Heart Arrest; Heart Massage; Humans | 2004 |
A patient responding to combined therapy with pirmenol and midodrine for refractory neurally mediated syncope complicated by prostatic hypertrophy.
Topics: Aged; Anti-Arrhythmia Agents; Humans; Male; Midodrine; Piperidines; Prostatic Hyperplasia; Syncope, | 2004 |
The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope.
Topics: Adaptation, Psychological; Adult; Aged; Anxiety; Cross-Sectional Studies; Depression; Fear; Female; | 2006 |
Midodrine for the treatment of vasovagal syncope (simple faint).
Topics: Child; Humans; Midodrine; Syncope, Vasovagal | 2006 |
A case of neurally mediated syncope induced by laughter successfully treated with combination of propranolol and midodrine.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Drug Therapy, Combination; Electrocard | 2007 |
Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy.
Topics: Administration, Oral; Adult; Drug Tolerance; Female; Humans; Male; Middle Aged; Midodrine; Sympathom | 1997 |
Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Clinical Protocols; Female; Follow-Up Studie | 1999 |
Syncope in pharmacologically unmasked Brugada syndrome: indication for an implantable defibrillator or an unresolved dilemma?
Topics: Adult; Bundle-Branch Block; Defibrillators, Implantable; Diagnosis, Differential; Electrocardiograph | 2001 |
Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension: introduction.
Topics: Clinical Trials as Topic; Humans; Hypotension, Orthostatic; Midodrine; Multicenter Studies as Topic; | 1995 |
Recurrent syncope in a 31-year-old army staff sergeant.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Case Management; Humans; Ma | 2002 |